Research
Print page Print page
Switch language
Rigshospitalet - a part of Copenhagen University Hospital
Published

Part I: Pituitary adenylate cyclase-activating polypeptide-38 induced migraine-like attacks in patients with and without familial aggregation of migraine

Research output: Contribution to journalJournal articleResearchpeer-review

Harvard

APA

CBE

MLA

Vancouver

Author

Bibtex

@article{0926ffa5e38b41948afda66a8703dd20,
title = "Part I: Pituitary adenylate cyclase-activating polypeptide-38 induced migraine-like attacks in patients with and without familial aggregation of migraine",
abstract = "BACKGROUND: Intravenous infusion of adenylate cyclase-activating polypeptide-38 (PACAP38) provokes migraine-like attacks in 65-70% of migraine sufferers. Whether aggregation of migraine in first-degree relatives contributes to this discrepancy in PACAP38-induced response is unknown. We hypothesized that genetic enrichment plays a role in triggering of migraine and that migraine without aura patients with a high family load ( ≥ 2 first-degree relatives with migraine) would report more migraine-like attacks after intravenous infusion of human PACAP38.METHODS: In this study, we allocated 32 previously genotyped migraine without aura patients to receive intravenous infusion of 10 pmol/kg/min PACAP38 and recorded migraine-like attacks including headache characteristics and associated symptoms. Information of familial aggregation was obtained by telephone interview of first-degree relatives using a validated semi-structured questionnaire.RESULTS: PACAP38 infusion induced a migraine-like attack in 75% (nine out of 12) of patients with high family load compared to 70% (14 out of 20) with low family load (P = 0.761). In an explorative investigation, we found that the migraine response after PACAP38 was not associated with the risk allele of rs2274316 (MEF2D), which confers increased risk of migraine without aura and may regulate PACAP38 expression.CONCLUSION: Migraine response to PACAP38 infusion in migraine without aura patients is not associated with high family load or the risk allele of rs2274316 (MEF2D).",
author = "Song Guo and Vollesen, {Anne Luise Haulund} and Hansen, {Rikke Dyhr} and Ann-Louise Esserlind and Amin, {Faisal Mohammed} and Christensen, {Anne Francke} and Jes Olesen and Messoud Ashina",
note = "{\textcopyright} International Headache Society 2016.",
year = "2017",
doi = "10.1177/0333102416639516",
language = "English",
volume = "37",
pages = "125--135",
journal = "Cephalalgia",
issn = "0333-1024",
publisher = "Wiley-Blackwell Publishing Ltd",
number = "2",

}

RIS

TY - JOUR

T1 - Part I

T2 - Pituitary adenylate cyclase-activating polypeptide-38 induced migraine-like attacks in patients with and without familial aggregation of migraine

AU - Guo, Song

AU - Vollesen, Anne Luise Haulund

AU - Hansen, Rikke Dyhr

AU - Esserlind, Ann-Louise

AU - Amin, Faisal Mohammed

AU - Christensen, Anne Francke

AU - Olesen, Jes

AU - Ashina, Messoud

N1 - © International Headache Society 2016.

PY - 2017

Y1 - 2017

N2 - BACKGROUND: Intravenous infusion of adenylate cyclase-activating polypeptide-38 (PACAP38) provokes migraine-like attacks in 65-70% of migraine sufferers. Whether aggregation of migraine in first-degree relatives contributes to this discrepancy in PACAP38-induced response is unknown. We hypothesized that genetic enrichment plays a role in triggering of migraine and that migraine without aura patients with a high family load ( ≥ 2 first-degree relatives with migraine) would report more migraine-like attacks after intravenous infusion of human PACAP38.METHODS: In this study, we allocated 32 previously genotyped migraine without aura patients to receive intravenous infusion of 10 pmol/kg/min PACAP38 and recorded migraine-like attacks including headache characteristics and associated symptoms. Information of familial aggregation was obtained by telephone interview of first-degree relatives using a validated semi-structured questionnaire.RESULTS: PACAP38 infusion induced a migraine-like attack in 75% (nine out of 12) of patients with high family load compared to 70% (14 out of 20) with low family load (P = 0.761). In an explorative investigation, we found that the migraine response after PACAP38 was not associated with the risk allele of rs2274316 (MEF2D), which confers increased risk of migraine without aura and may regulate PACAP38 expression.CONCLUSION: Migraine response to PACAP38 infusion in migraine without aura patients is not associated with high family load or the risk allele of rs2274316 (MEF2D).

AB - BACKGROUND: Intravenous infusion of adenylate cyclase-activating polypeptide-38 (PACAP38) provokes migraine-like attacks in 65-70% of migraine sufferers. Whether aggregation of migraine in first-degree relatives contributes to this discrepancy in PACAP38-induced response is unknown. We hypothesized that genetic enrichment plays a role in triggering of migraine and that migraine without aura patients with a high family load ( ≥ 2 first-degree relatives with migraine) would report more migraine-like attacks after intravenous infusion of human PACAP38.METHODS: In this study, we allocated 32 previously genotyped migraine without aura patients to receive intravenous infusion of 10 pmol/kg/min PACAP38 and recorded migraine-like attacks including headache characteristics and associated symptoms. Information of familial aggregation was obtained by telephone interview of first-degree relatives using a validated semi-structured questionnaire.RESULTS: PACAP38 infusion induced a migraine-like attack in 75% (nine out of 12) of patients with high family load compared to 70% (14 out of 20) with low family load (P = 0.761). In an explorative investigation, we found that the migraine response after PACAP38 was not associated with the risk allele of rs2274316 (MEF2D), which confers increased risk of migraine without aura and may regulate PACAP38 expression.CONCLUSION: Migraine response to PACAP38 infusion in migraine without aura patients is not associated with high family load or the risk allele of rs2274316 (MEF2D).

U2 - 10.1177/0333102416639516

DO - 10.1177/0333102416639516

M3 - Journal article

C2 - 26994299

VL - 37

SP - 125

EP - 135

JO - Cephalalgia

JF - Cephalalgia

SN - 0333-1024

IS - 2

ER -

ID: 49697092